We use cookies and other technologies on this website to enhance your user experience.
By clicking any link on this page you are giving your consent to our Privacy Policy and Cookies Policy.
日本版敗血症診療ガイドライン2024 【アプリ版】 icon

1.1.8 by 株式会社Smart119


Nov 19, 2024

About 日本版敗血症診療ガイドライン2024 【アプリ版】

You can immediately refer to the Sepsis Treatment Guidelines 2024 at the bedside.

This app was developed for the purpose of disseminating the Japanese Sepsis Treatment Guidelines 2024 (J-SSCG2024) by having it used at the bedside. The main part of J-SSCG2024 can be viewed at the following URL. This app summarizes the contents of the main story. Please refer to the main content as appropriate.

Main URL: https://www.jsicm.org/news/news240606-J-SSCG2024.html

In addition to viewing guidelines for each CQ, links to clinical flow, bookmark function, scoring function (SOFA score, Early Warning Score), and tag search function, this app has new functions such as clinical scenarios, reference links, and free words. A search function, questionnaire function, notification function, and antibiotic recommendation display have been added. The theme is "Applications that are easier to use at the bedside/that people will want to use."

Please use all means.

What's New in the Latest Version 1.1.8

Last updated on Nov 19, 2024

Minor bug fixes and improvements. Install or update to the newest version to check it out!

Translation Loading...

Additional APP Information

Latest Version

Request 日本版敗血症診療ガイドライン2024 【アプリ版】 Update 1.1.8

Uploaded by

انا وانت ياغالي

Requires Android

Android 10.0+

Available on

Get 日本版敗血症診療ガイドライン2024 【アプリ版】 on Google Play

Show More

日本版敗血症診療ガイドライン2024 【アプリ版】 Screenshots

Subscribe to APKPure
Be the first to get access to the early release, news, and guides of the best Android games and apps.
No thanks
Sign Up
Subscribed Successfully!
You're now subscribed to APKPure.
Subscribe to APKPure
Be the first to get access to the early release, news, and guides of the best Android games and apps.
No thanks
Sign Up
Success!
You're now subscribed to our newsletter.